Parthymos Ioannis, Kostapanos Michael S, Liamis George, Florentin Matilda
Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece.
Lipid Clinic, Department of General Medicine, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
J Cardiovasc Dev Dis. 2022 Jan 25;9(2):42. doi: 10.3390/jcdd9020042.
Hypertriglyceridemia has been identified as a risk factor for cardiovascular disease and acute pancreatitis. To date, there are only few drug classes targeting triglyceride levels such as fibrates and ω-3 fatty acids. These agents are at times insufficient to address very high triglycerides and the residual cardiovascular risk in patients with mixed dyslipidemia. To address this unmet clinical need, novel triglyceride-lowering agents have been in different phases of early clinical development. In this review, the latest and experimental therapies for the management of hypertriglyceridemia are presented. Specifically, ongoing trials evaluating novel apolipoprotein C-III inhibitors, ω-3 fatty acids, as well as fibroblast growth 21 analogues are discussed.
高甘油三酯血症已被确认为心血管疾病和急性胰腺炎的危险因素。迄今为止，仅有几类药物可针对甘油三酯水平，如贝特类药物和ω-3脂肪酸。这些药物有时不足以应对极高的甘油三酯水平以及混合性血脂异常患者残留的心血管风险。为满足这一未被满足的临床需求，新型降甘油三酯药物已处于早期临床开发的不同阶段。在本综述中，介绍了治疗高甘油三酯血症的最新及实验性疗法。具体讨论了正在进行的评估新型载脂蛋白C-III抑制剂、ω-3脂肪酸以及成纤维细胞生长因子21类似物的试验。
